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According to the American Society for Testing and Materials, nanoparticles (NPs) are characterized by having two
or more dimensions at the nanometer scale and distinctive improved physical/chemical properties compared with
their bulk counterpart. Considering their composition, NPs are usually divided into three principal categories:
inorganic (metals, metal oxide, ceramic and quantum dots), organic (polymers and lipid-based assembles) and
carbon-based NPs [1]. Nano-sized particles exhibit distinctive, chemical and physical properties that denote them as
unique nanodevices usable in a wide range of pharmaceutical/therapeutic applications for their capability to affect
directly cell vitality or for their drug delivery attitude [2]. They are playing a strategic role in the implementation
of new therapeutic solutions against Parkinson’s, Alzheimer and infectious diseases, as well as against cancer and
many other disorders [3,4]. Usually, the main challenge is to achieve well-dispersed NPs, even in a colloidal manner,
in order to facilitate their use both in in vitro and in vivo tests, in other words, for internalization, vitality,
differentiation assays and so on. It is therefore required to oversee their size and shape and hence avoid aggregation
and agglomeration in body fluids or in cell culture media, both containing proteins, electrolytes, lipids and other
biomolecules. As soon as the NPs come into contact with biological fluids, their surface adsorbs a wide range of
biomolecules, forming a protein corona which is assumed to comprise a hard layer and a soft one. The former is
closely associated with the NP, while the soft layer consists of loosely bound proteins. Many parameters affect NPs’
protein corona composition and subsequently their aggregation state and, ultimately, their therapeutic applicability.
The presence of a protein corona on NPs dispersed in a biological fluid is unanimously recognized, as well as the
fact that it can hugely affect their size, shape and charge [5].
By controlling and measuring the NPs’ colloidal stability and aggregation, researchers can have a clear idea of
how these factors affect biodistribution, toxicity and pharmacokinetic parameters. Until now different solutions
have been implemented to escape the agglomerates’ formation in physiological solutions and media.
Nanoparticle dispersion in aqueous media can be described by using the Deryagin, Landau, Verwey and Overbeek
(DLVO) theory which takes into account the Van der Waals attractive forces and the electrostatic interactions,
allowing assessment of the potential barrier between particles.
In this commentary, we will analyze the role of various dispersant enhancers, including chemical, biological and
physical approaches. Actually, dispersion stabilizers as a chemical modification of the NP surfaces are routinely
applied at the preparation step of the nanomaterials. Such chemical functionalization includes the use of organic
coatings, such as various natural and synthetic polymeric layers. Biologically relevant approaches rely on the
use of proteins and lipid bilayers, both from synthetic or natural origins, to shield NPs against aggregation in a
biologically relevant environment. For physical methods, the application of ultrasound as a pretreatment to improve
NP dispersion is applied regularly for deagglomeration of NPs into biological media.
Nanomedicine (Lond.) (Epub ahead of print) ISSN 1743-588910.2217/nnm-2019-0070 C© 2019 Tania Limongi et al.
Commentary Limongi, Canta, Racca et al.
Chemical approaches to improve NP dispersion
In general, the most manageable strategy consists on the stabilization through NPs surface chemistry modification
by using PEG coatings, zwitterionic ligands, lipid bilayers, proteins, glycans, mercaptoalkyl acid ligands and/or
aptamers.
A common practice to guarantee efficient NPs dispersion time is the so called ‘PEGylation’ strategy. The
use of PEG to coat NPs has many advantages, such as reduced aggregation, phagocytosis and opsonization,
which therefore decrease NPs immunogenicity and improve blood half-life, in other words, improved systemic
circulation. PEG coating on NPs reduces their nonspecific adsorption of serum proteins and their uptake by the
mononuclear phagocytic system [6]. Even if proteins can interact with the PEG coatings, the recognition systems fail
to identify the underlying NPs as foreign bodies; in fact, PEG-modification of liposomes considerably increases NPs’
circulation times. The first PEGylated nanoparticle product was approved by the US FDA in 1995 for treatment of
Kaposi’s sarcoma. PEGylated liposomal doxorubicin (PEG-LD), Doxil ‘Stealth R©’ liposomes, increased doxorubicin
bioavailability by nearly 90-fold at 1 week from injection versus the free drug, with a drug half-life of 72 h and a
circulation half-life of 36 h [7]. One of the most diffused methodologies used to coat NPs with PEG is through the
functional-terminated PEG. As a broadly employed example, thiol-terminated derivatives (PEG-SH) can covalently
bind to gold (Au) NPs’ surface. In particular, highly dispersed and stable Au NPs in high ionic strength solutions
are citrate-stabilized ones; they can be produced by adding a solution of PEG-SH with the desired molecular
weight and allowing citrate ligands to gradually exchange with PEG-SH [8]. It should be noted that only spherical-
shaped Au NPs can be obtained using citrate buffers, while surfactants as cetyltrimethylammonium bromide
(CTAB) are required to define, in high ionic strength solutions, stable anisotropic-shaped nanostructures such as
Au nanorods. Methods using PEG-SH ligand exchange reactions have been implemented to replace CTAB with
PEG molecules [9]. Considering metal oxide-based NPs, several solutions for guaranteeing an appreciable colloidal
stability are again to link functional PEG onto them through a covalent bond or by using silane-terminated
PEG [10]. In particular, different silane-terminated PEGs with various molecular weights (from 550 to 5000 Da)
were covalently bound to colloidal mesoporous silica NPs during a sol-gel co-condensation approach. The different
PEGylation strategies were then evaluated on the long-term biostability of such mesoporous silica NPs when
dispersed in artificial plasma. These experiments demonstrated that longer and denser PEGylated shells are most
efficient in preserving the colloidal stability and reducing the biodegradation kinetics of mesoporous NPs in
comparison to unfunctionalized ones [10]. Considering another type of nanomaterial, CdTe/CdS/ZnS quantum
dots can be directly produced in water by using PEG as the stabilizing agent. Although PEGylation of NPs provides
a postsynthetic reproducible functionalization system for enhancing colloidal stability in physiological media, it
causes an increase in the NP hydrodynamic size and, especially during in vivo experiments, the host can often
develop antibodies against PEG-encapsulated nanocarriers [8].
Zwitterionic ligands, including carboxybetaines and sulfobetaines, containing two or more functional groups
with net zero charge, have been described as exceptional ligands for improving NPs’ stability in biofluids. Indeed,
they customize NPs with smaller hydrodynamic radii and consequently create a lower grade of opsonization.
Regrettably, minor changes in pH can change their behavior, moreover most of them are not yet commercially
available and their use involves difficult synthesis procedures.
Mercaptoalkyl acid ligands, such as the 11-mercaptoundecanoic acid (MUA), are also used for NPs surface
chemical functionalization. However, it should be noted that they guarantee less colloidal stability then PEG
coatings, because they are highly pH-dependent.
Nanoparticles stability has also been enhanced through thiol- or amino-modified aptamers immobilization.
Negatively charged aptamer-modified Au NPs remained more stable in high salt solutions as the negative charge
inhibits aggregation caused by electrostatic repulsion forces [11]. The principal drawback of aptamer coatings is
associated with the low commercial availability of their expensive library.
Glycan add-ons can also modify NPs’ properties by enhancing their biocompatibility and solubility. Polysac-
charides such as chitosan, dextran, hyaluronic acid and heparin can enable the preparation of a wide range of
polysaccharide-based NPs for pharmaceutical and therapeutic applications. Heparin-coated metal oxide NPs, such
as colloidal mesoporous silica NPs, have shown improved biostability in blood and efficient antithrombogenic
effects, when compared with pristine mesoporous silica NPs [12]. In this example, heparin was covalently bound
to the outer surface of amino-functionalized mesoporous silica NPs. The authors claimed that the combination of
heparin with the highly porous features of mesoporous NPs can lead to an efficient multifunctional drug-delivery
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system. This smart all-in-one nanosystem can thus act both as an anticoagulant drug, thanks to heparin itself,
and as a carrier, in other words, further incorporating other biologically functional molecules or therapeutics as
deliverable cargos.
Biological approaches for particle dispersal
Another strategy to increase the stability of NPs in biological fluids is protein coatings; proteins are stable under
physiological conditions through their multitude of charged groups, able to endow NPs with steric and electrostatic
stabilization. The protein coating on NPs precludes the adhesion of other proteins by causing a hydration shell
through hydrogen bonds with surrounding water molecules. The main concern related with protein coating strategy
is the increase in the hydrodynamic diameter of the final NPs.
Additional approaches, inspired by natural materials and processes, concern the thermodynamic and physiological
aspects of cell membranes. Indeed, the use of synthetic and biologically derived lipid bilayers and membranes
as coating agents allows stabilization of NPs in biological media and human fluids. Lipid bilayers have been
successfully used to produce highly homogeneous thin envelopes on NPs surface [13], representing a valid tool for
NP delivery in biological fluids thanks to their resemblance to biological membranes. Usually, a lipid film formation
represents the first step of NPs lipid bilayer coating; lipids such as cholesterol (Chol), dioleoylphosphatidylcholine
(DOPC), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) and egg sphingomyelin (ESM) are run together
in a chloroform/methanol mixture, dried under a stream of argon and subjected to a vacuum to remove any trace
of residual solvent. For the encapsulation, multilamellar vesicles are obtained when NPs are added and sonicated
in the lipid films previously hydrated with water; additional sonication are required to reduce the multilamellar
vesicles into smaller unilamellar ones containing NPs. In another encapsulation approach, a process called ‘solvent
exchange’ method is proposed. The NPs are dispersed in a solvent solution of free-floating lipids and then the water
concentration is promptly increased, leading to the formation of lipid bilayers supported on the NP surface [14,15].
The stability and the long circulating capability of liposomes are still debated along with the fact that their circulation
could cause some side effects. It is therefore believed that liposome-encapsulated NPs can guarantee a higher and
prolonged stabilization with respect to pristine liposomes and have the advantage of being able to carry a higher
amount of therapeutic cargo, in other words, drugs or genes, when highly porous NPs are concerned [14].
In a context of translation toward personalized medicine, extracellular vesicles (EVs) such as exosomes, could be
a better choice in terms of bio- and hemo-compatibility, lower immunogenic content, in case of autologous EVs,
and, probably, higher dispersion in human biological fluid than artificial liposomes. Examples of NP encapsulation
strategies in exosomes were thus proposed [16,17], with the main aim of improving the delivery of anticancer drugs
to cell cultures in vitro. In any case, it must be emphasized that the absence of covalent binding onto NP surfaces
can be the cause of lipid detachment, and, although lipid coatings stabilize NPs in different biological media, some
NP aggregation phenomena have been observed when dispersed in media characterized by high concentrations of
cysteine or glutathione [8]. Furthermore, NPs encapsulated into EVs can raise some doubts in terms of encapsulation
efficiency, as well as when high yield of the final hybrid materials and low cost-related productions are desired.
Physical dispersion methods
Prior to performing in vitro or in vivo tests, dry powders or suspensions of NPs must be dispersed in the final
medium while maintaining their nanometric size. When dried, NPs are bound together into micro/macrometric
structures by both weak physical Van Der Waals forces and strong chemical bonds. Moreover, the high surface area to
volume ratio of nanometric particles further increases the interparticle physical attractive forces. To break down and
disrupt NP agglomerates, the application of high frequency pressure waves, commonly referred to as ‘sonication’,
is one of the most widely used techniques. Sonication relies in the application of pressure waves at a frequency
higher than 20 KHz to the NP suspension to disrupt the particle agglomerates through a process called inertial
cavitation. Inertial cavitation refers to the instable oscillation of gas bubbles in liquid due to the applied acoustic
pressure. Indeed, when a gas bubble is exposed to an alternating acoustic field, it expands and contracts following
the external pressure. When the applied acoustic pressure is higher than the cavitation threshold, the oscillation of
the bubble becomes unstable and it violently collapses, generating shock waves and high temperatures at the center
of the collapse [18]. The cavitation-induced mechanical effects, such as localized high pressures and shock waves,
are the main mechanisms behind NP dispersion by ultrasound. Ultrasound disruption is more energy-efficient and
can achieve a higher degree of NP dispersion and optimal deagglomeration, at constant input energy, than other
conventional dispersion techniques. Moreover, ultrasound dispersion is a convenient, relatively inexpensive tool
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that is simple to operate and maintain [19]. Furthermore, there are evidences that ultrasound application to NP
suspension preceding the addition of a dispersion stabilizer can be more effective than sonication afterward. In a
comparison study on titania (TiO2) NP dispersions, two different mechanical dispersion techniques were applied:
ultrasonic irradiation and milling with micrometer beads. Ultrasound irradiation resulted in lower aggregate size
than milling, thus concluding that ultrasonic dispersion method was a useful way to prepare concentrated and
highly dispersed NP suspensions [20]. Therefore, ultrasonic treatment of NP suspension can be considered as an
effective and nonexpensive physical method to obtain dispersed NPs, as part of a multistep approach toward stable
NP suspensions for in vitro and in vivo therapeutic applications.
Conclusion
In conclusion, it seems clear that for testing the effects of NPs on in vitro cells cultures and their in vivo fate, they
have to be effectively dispersed in body fluids such as blood, urine, interstitial fluid and so on. It is evident through
this commentary that therapies for cancer, infections such as HIV, or for other chronic and acute illnesses, have
strongly benefited from the use of nanotechnology tools. The nanomedicine approach thus broadly benefits from
improving the dissolution mechanisms of drugs via NP formulation. By tuning NP size and surface properties,
researchers and physicians could have a clear indication of how these factors affect the NP biodistribution and they
will certainly increase their chances of optimizing drug stability by decreasing their clearance and potential side
effects in nanomedical approaches.
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